



Supplementary Figure 1


A




B



C



D




Supplementary Figure 2

A

AYA patients (18 – 40 years)

2010 – 2020

	Median OS	HR (95% CI)	p value
SEER:	NR	–	–
UChicago:	84 mo	0.98 (0.67 – 1.43)	0.94



Number at risk


SEER:	3514	2004	1274	769	419	122
UC:	93	56	23	13	9	6

B

Older patients (>40 years)

2010 – 2020

	Median OS	HR (95% CI)	p value
SEER:	23 mo	–	–
UChicago:	53 mo	0.70 (0.56 – 0.88)	0.003



Number at risk

SEER:	4475	1672	902	526	247	75
UC:	128	56	27	16	10	7

Supplementary Table 1**UChicago B-ALL patients (n= 178)**

	N	NHW (n= 112)	Hispanic (n= 44)	NHB (n= 22)
Inotuzumab	37	23 (20.5)	10 (22.7)	4 (18.1)
Blinatumomab	36	25 (22.3)	9 (20.4)	2 (9)
Cellular therapy	42	27 (24.1)	12 (27.2)	3 (7.1)